Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Infectious diseases
- Publicado em
- 21 abr 2026
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial
Maria Lara-Escandell, Lina Sánchez, Dídac Macià, Chenjerai Jairoce, Maxmillian Mpina, Hermann Sorgho, Selidji Todagbe Agnandji, David Dosoo, Ben Gyan, Marta Vidal et al.
Descritores MeSH
- Antibodies, Protozoan
- Immunoglobulin G
- Plasmodium falciparum
- Protozoan Proteins
- Malaria, Falciparum
- Malaria Vaccines
- Female
- Humans
- Vaccination
- Infant
Veja também
Estudos relacionados
- The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial
- Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial
- Magnitude and durability of ProC6C-AlOH/Matrix-Mtm vaccine-induced malaria transmission-blocking antibodies in Burkinabe adults from a Phase 1 randomized trial
- Identification of RTS,S/AS01 vaccine-induced humoral biomarkers predictive of protection against controlled human malaria infection